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Abstract
Background: The E-selectin ligands expressed by cancer cells mediate adhesion of circulating cancer cells to
endothelial cells, as well as within tissue microenvironments important for tumor progression and metastasis. The
identification of E-selectin ligands within cancer tissue could yield new biomarkers for patient stratification and aid
in identifying novel therapeutic targets. The determinants of selectin ligands consist of sialylated tetrasaccharides,
the sialyl Lewis X and A (sLeX and sLeA), displayed on protein or lipid scaffolds. Standardized procedures for
immunohistochemistry make use of the antibodies against sLeX and/or sLeA. However, antibody binding does
not define E-selectin binding activity.
Methods: In this study, we developed an immunohistochemical staining technique, using E-selectin-human Ig
Fc chimera (E-Ig) to characterize the expression and localization of E-selectin binding sites on paraffin-embedded sections of
different cancer tissue.
Results: E-Ig successfully stained cancer cells with high specificity. The E-Ig staining show high reactivity scores in colon and
lung adenocarcinoma and moderate reactivity in triple negative breast cancer. Compared with reactivity of antibody against
sLeX/A, the E-Ig staining presented higher specificity to cancer tissue with better defined borders and less background.
Conclusions: The E-Ig staining technique allows the qualitative and semi-quantitative analysis of E-selectin binding activity
on cancer cells. The development of accurate techniques for detection of selectin ligands may contribute to
better diagnostic and better understanding of the molecular basis of tumor progression and metastasis.
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Background
Metastasis is initiated when cancer cells leave the primary
tumor and disseminate to other parts of the body, where
these cells are able to proliferate and form new tumors.
The metastasis of vital organs such as the liver, lungs, and
bones is commonly initiated from the dissemination of
tumor cells through bloodstream. A key and early step of
the hematogenous metastasis is the contact of blood-
circulating cancer cells with the endothelium. Cancer cells
expressing relevant sialofucosylated glycan determinants
bind to the endothelial selectins, E- and P-selectin, thereby
establishing adhesive interactions with endothelium that
resist hemodynamic shear forces. This initial “shear-resist-
ant” adhesion step is requisite for the transendothelial mi-
gration of cancer cells from blood into tissues [1]. Since
the endothelial selectins are inducible by inflammatory cy-
tokines and expressed constitutively on marrow microvas-
culature [2, 3], cancer cell binding to selectin is likely to
contribute for cancer cell migration to selectin-rich
niches, such as inflammation sites and the bone. In
addition to their roles in cell adhesion and transendothe-
lial migration, binding to selectins also initiates signal
transduction that may promote cancer progression. As an
example, in colon cancer, diverse cellular functions such
as the activation of SAPK2/p38 [4] and tyrosine phosphor-
ylation of several proteins are induced following engage-
ment of E-selectin ligands [5].
The prototypical selectin binding motif consists of the
tetrasaccharide sialyl Lewis X (sLeX; NeuAc-α(2,3)-Gal-
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β(1,4)-[Fuc-α(1,3)]GlcNAc-R), or its stereoisomer sialyl
Lewis A (sLeA, NeuAc-α(2,3)Gal-β(1,3)-[Fuc-α(1,4)
]GlcNAc-R) [5]. The expression of both sLeX and/or
sLeA is observed in various cancers in a progressive
fashion, increasing in expression from normal tissue to
early stage cancer to metastatic disease [6, 7]. In vitro,
the expression of sLeX/A by cancer cells correlates with
the cancer cell ability to bind endothelial selectins [8]. In
tumor tissue, sLeX/A expression has been correlated with
the metastasis formation by several cancer types, such as
colon carcinoma, lung adenocarcinoma and breast cancer
[9–12]. In colorectal cancers, the expression of sLeX/A in
the primary lesion is considered a good marker for
assessing the metastatic proclivity of colorectal cancer
[13]. Indeed, expression of these determinants is also
correlated with the extent of malignancy, high incidence
of recurrence and with decreased survival of patients [14].
Importantly, the well-recognized clinically-relevant tumor
marker CA19–9 is sLeA [15].
Nevertheless, the prognostic value of the detection of the
carbohydrates sLeX or sLeA, as a sole measure to evaluate
selectin ligands, is controversial [16, 17]. The identification
of selectin ligands is generally performed using
monoclonal antibodies that recognize sLeX and sLeA, such
as HECA-452, in standardized protocols [9, 10, 18]. Other
antibodies developed so far don’t recognize simultaneously
both glycans, such as CLEX-1, CA19–9 that recognizes
sLeX and CA19–9, respectively. Additionally, it is
questionable whether HECA-452 antibody mimic E-
selectin binding [19]. Binding to E-selectin itself, is more
specific for identification of E-selectin binding activity dis-
played on specific protein scaffolds [5, 20]. In addition,
there are minor sialofucosylated glycans, which are also
carbohydrate determinants of E-selectin ligands, that are
not recognized by any current monoclonal antibody [21].
In this study, we developed a novel staining protocol for
paraffin-embedded slides of colon cancer tissues, using a
mouse E-selectin-human Ig Fc chimera (E-Ig), a validated
tool to identify E-selectin ligands in human cells [22, 23].
The E-selectin ligand staining protocol described here
stains colon adenocarcinoma cells, as well as other cancer
tissue, and produces a consistent membrane staining with
little background compared to current staining protocols
using antibodies against sLeX and sLeA.
Methods
This study used several slides of two cases of colon
adenocarcinoma, one case of normal colon tissue, two
cases of triple negative breast cancer and two cases of
lung adenocarcinoma. Formalin fixed paraffin-embedded
tissue are sectioned and placed onto slides using stand-
ard paraffin microtomy. The Lab Vision PreTreatment
Module (PTM) from Thermo Scientific, is used for de-
paraffinization and antigen retrieval on tumor sections.
After blocking endogenous peroxidases, slides are stained
using a three-step procedure with the E-Ig, anti-CD62E
and HRP polymer. All the steps in these protocols take
place at room temperature. All reagents used are listed in
Table 1. All procedures were performed under the approval
of the Ethics Committee of Hospital CUF Descobertas.
1. De-paraffinization and heat-induced antigen
retrieval
1.1.Place 2-μm thick sections of formalin fixed
paraffin-embedded tissue on glass slides
(Superfrost Plus, Thermo Scientific) made to
ensure firm electrostatic attraction of the tissue
sections.
1.2.Dry slides on oven at 37 °C overnight.
1.3.Prepare the laboratory instrument, Lab Vision
PreTreatment Module (PTM) from Thermo
Scientific, to perform de-paraffinization and
antigen retrieval of tumor tissue:
1.3.1. Fill each of the PTM tanks with 1.5 L of
the Trilogy Pretreatment Solution 1× and
program PTM to preheat to 60 °C and heat
to 94 °C for 20 min.
1.3.2. Start the pre-heating cycle and then
mount the slides into the racks and place
them into the PTM.
1.3.3. Start the heating cycle, which will heat to
94 °C and then cool down to 60 °C.
1.3.4. After the heating cycle has finished, take
racks out of PTM and wash slides well with
distillated water for 1–5 min.
1.4.Immerse the slides in 70% ethanol for 10 s.
1.5.Immerse the slides in 96% ethanol for 10 s.
1.6.Immerse the slides in 100% ethanol for 10 s.
Repeat once.
2. Blockade of endogenous peroxidases
2.1.Place slides in peroxidase block solution
(3% H2O2) for 15 min.
2.2.Wash the slides with tap water for 1–2 min.
2.3.Place the slides in a humidity chamber to avoid
the drying of the tissue during the entire
staining process. Rinse slides with Tris-Buffered
Saline solution with 0.1% Tween 20 (TBST), and
leave in TBST for 5 min; repeat one more time.
2.4.Wipe off the excess of solutions around the
tissue on the slides. Mark a circle around the
tissue with a hydrophobic pen.
2.5.Rinse slides with TBST and then leave for 5 min
in TBST.
3. Staining with chimeric molecules & antibody:
3.1.Mouse E-selectin-human Ig Fc chimera (E-Ig)
3.1.1. Incubate slides with 1:300 dilution of
recombinant mouse E-selectin-human Ig Fc
chimera (E-Ig) in “Diamond: Antibody
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Diluent”, for 30 min. The final E-Ig
concentration is 1.67 μg/mL.
3.1.2. Rinse slides with TBST, then place in
TBST for 5 min. Repeat once.
3.1.3. Incubate slides with 1:250 dilution of rat
anti-mouse E-selectin (CD62E) monoclonal
antibody in 100 μL of “Diamond: Antibody
Diluent”, for 30 min. The final antibody
concentration in TBST is 2 μg/mL.
3.1.4. Rinse slides with TBST, then place in
TBST for 5 min. Repeat once.
3.1.5. Incubate slides with the “HiDef Detection
HRP Polymer System”, which detects the
primary antibody by amplification of
antibody (Amplifier) followed by HRP
polymer (Detector), explicitly:
3.1.5.1.Incubate slides with “HiDef Detection
Amplifier”, for 10 min.
3.1.5.2.Rinse slides with TBST, then place in
TBST for 5 min. Repeat once.
3.1.5.3.Incubate slides with “HiDef Detection
HRP Polymer Detector”, for 10 min.
3.1.6. Rinse slides with TBST, then place in
TBST for 5 min. Repeat once.
Notes: All solutions in the staining process should have
2 mM CaCl2. As negative control, the same staining
protocol run without the E-Ig or without the rat anti-
mouse CD62E monoclonal antibody or by adding EDTA
(final concentration of 10 mM) to all the solutions (TBST
and “Diamond: Antibody Diluent”) during the staining
process.
3.2.Staining with anti-sLeX and anti-sLeA antibody
HECA-452
3.2.1. Incubate slides with 1:50 dilution of rat anti-
sLeX and -sLeA monoclonal antibody (clone
HECA-452) in 100 μL of “Diamond: Antibody
Diluent”, for 1 h. The final antibody concentration
is 10 μg/mL.
3.2.2. Rinse slides with TBST, then place them in
TBST for 5 min. Repeat once.
3.2.3. Incubate slides with “HiDef Detection HRP
Polymer System”:
3.2.3.1.Incubate slides with “HiDef Detection
Amplifier”, for 10 min.
3.2.3.2.Rinse slides with TBST, then place in
TBST for 5 min. Repeat.
3.2.3.3.Incubate slides with “HiDef Detection
HRP Polymer Detector”, for 10 min.
3.2.4. Rinse slides with TBST, then place in TBST
for 5 min. Repeat once.
4. Chromogenic detection of HRP and Hematoxylin
staining
4.1.Combine 1 part of chromogen concentrate, the
DAB, with 20 parts of DAB substrate and mix
thoroughly.
Table 1 List of commercial reagents used in this study
Name Company (Country) Catalog Number Comments
Lab vision PT Module Thermo scientific (USA)
Trilogy Pretreatment Solution Cell Marque (USA) 920P Diluted to 1× with ddH2O
Ethanol AGA (Portugal) 4.006.16.00.00 Used in 70% and 96% solution and pure.
Peroxidase block solution Atom Scientific (United Kingdom) GPC8054-E
TBS IHC wash buffer with Tween 20 Cell Marque 935B-09 Diluted to 1× with ddH2O
Diamond antibody diluents Cell Marque 938B-09
Hi-Def Detection HRP Polymer System Cell Marque 954D-30 A polymer containing anti-rat Ig Fc conjugated
with HRP
DAB Chromogen/Substrate Bulk Pack
(High Contrast)
ScyTek Laboratories (USA) ACV500 A pack of chromogen concentrate, the
3,3′-Diaminobenzidine tetrahydrochloride
(DAB) and DAB substrate
Xylene Klinipath Netherland (The Netherland) 4055.9005
Mayer’s Hematoxylin Bio-Optica (Italy) 05–06002/L
Quick-D Mounting Medium Klinipath Nederland 7281
Coverslips Thermo Scientific 4951PLUS4
Humidity chamber Bio-Optica
E-Ig chimera R&D Systems (USA) 575-ES-100 Diluted to 1:300 in Diamond: Antibody Diluent
Rat anti-mouse CD62E BD Biosystems (USA) 550,290 Diluted to 1:250 in Diamond: Antibody Diluent
Anti-sLeX/A (HECA-452) Biolegend (USA) 321,302 Diluted to 1:50 in Diamond: Antibody Diluent
Carrascal et al. BMC Cancer  (2018) 18:495 Page 3 of 10
4.2.Apply the mix substrate solution to the slide.
Incubate slides for 3 min. Positive staining
produces a dark brown reaction product.
4.3.Immediately after the colour development, wash
slides with tap water for 1–2 min.
4.4.Incubate slides in hematoxylin, which stains
nucleic acids, for 3 min.
4.5.Wash slides with warm tap water for 1–2 min
in order to blueing hematoxylin stain.
5. Dehydration and Mounting
5.1.Immerse the slides in 70% ethanol for 10 s.
5.2.Immerse the slides in 96% ethanol for 10 s.
5.3.Immerse the slides in 100% ethanol for 10 s.
Repeat once.
5.4.Immerse the slides in xylene for 10 s. Repeat
once.
5.5.Add one drop of Quick-D mounting medium to
the slide and place the coverslip.
6. Tissue slide evaluation
6.1.Slides were visualised under a light microscope
with coupled camera. A semi-quantitative
approach was established for tissue slide
evaluation, according to Lin and Prichard (2015)
recommendations [24]. The scores used in the
classification protocol to evaluate cell staining
were 0 when negative, 1 if < 25%, 2 if 26–50%, 3
if 51–75% and 4 if > 75% cells were stained. The
scores used in the classification protocol to
evaluate staining intensity were 0 when no stain
was found, 1 if weak, 2 if intermediate, 3 if
strong staining intensity was found. The total
semi-quantitative value used to quantify E-Ig
and antibody staining in this study combined
the two above mentioned scores, and was
calculated by multiplying each of the two scores.
Results
In this study, we first tested the use of a chimeric mouse E-
selectin fused to the human Fc region of immunoglobulins
(i.e., mouse E-selectin-human Ig Fc chimera (E-Ig)) to stain-
ing of E-selectin ligands in colon adenocarcinoma tissue.
The E-Ig staining technique is a three-step procedure that
includes an incubation with E-Ig, followed by incubation
against E-selectin (anti-CD62E) and then incubation with a
polymer of anti-rat Ig Fc conjugated with horseradish per-
oxidase (HRP), hereafter named HRP polymer (Fig. 1). As
shown in Fig. 2, this technique allowed a successful immu-
nohistological staining demonstrated by the brown staining
on cancer tissue, obtained after 3,3′-diaminobenzidine tet-
rahydrochloride (DAB) color - enzyme detection. The E-Ig
staining was strong in colon adenocarcinoma tissue (with a
score 3 of cell staining and an intensity of score 4, total
score = 12), showing a scattered pattern with stronger re-
activity within crypts. The strongest staining signal was on
the goblet cells in their apical pole (Fig. 2a-d). The lamina
propria showed E-Ig staining exclusively on nests of neo-
plastic cells (Fig. 2a and c). Staining was not detected (total
score = 0) in the control assays, run in the absence of anti-
CD62E (Fig. 3a and b), or absence of E-Ig (Fig. 3c), or when
assays were performed in presence of a calcium chelator
(EDTA) (Fig. 3d), thus confirming the specificity of E-Ig
staining.
As E-selectin ligands have been inferred by others using
antibodies against sLeX/A glycans, we compared the E-Ig
staining profile with the immunohistochemical expression
profile of colon cancer tissues stained with antibody that
recognize both sLeX and sLeA, the HECA-452 clone.
HECA-452 staining was in general stronger (with a score
3 (or 4) of cell staining and an intensity of score 4, total
score = 12 (or 16)). Yet, the major differences were quanti-
tative, as the lamina propria showed scattered HECA-452
staining, which was not exclusive of neoplastic cells nor
stained by E-Ig chimera (Fig. 4a, b).
We have also compared staining in normal colon tis-
sue. As shown in Fig. 4, the strongest staining was in
goblet cells (Fig. 4c, d) and negligible staining in the
lamina propria.
HECA-452 staining was stronger in the goblet cells of
the crypt similarly to the histochemical profile with E-Ig
staining of normal colon tissue (Fig. 4c, d).
Thus, from the comparison of results obtained from E-
Ig or HECA-452 staining protocols, it is possible to con-
clude that both protocols stain tumor tissue and normal
goblet cells. However, there are quantitative differences in
tumor staining, as E-Ig chimera staining generates a spe-
cific and clearer staining, while HECA-432 staining is scat-
tered, mainly within the lamina propria.
We have also evaluated the efficacy/universality of E-
Ig staining in different types of cancer tissue, namely in
triple negative breast cancer and in lung adenocarcin-
oma. As shown in Fig. 5, E-Ig chimera staining in triple
negative breast cancer (Fig. 5a, c) is weaker (with a score
2 of cell staining and an intensity of score 2, total score
= 4), in relation to the above-mentioned E-Ig staining in
colon adenocarcinoma. Nevertheless, in lung adenocar-
cinoma E-Ig chimera staining is as strong (Fig. 5e, g) as
in colon adenocarcinoma (with a score 3 of cell staining
and an intensity of score 4, total score = 12). Staining
using E-Ig chimera on either breast or lung adenocarcin-
oma were slightly stronger with more clear staining of
neoplastic tissue and borders, than respective HECA-
452 staining (Fig. 5b, d, f, h).
Discussion
Immunohistochemical staining of selectin ligands has been
inferred in prior studies for a variety of cancers, based on
the expression of sLeX/A, detected by appropriate
antibodies [9, 10, 18]. These studies have highlighted that
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Fig. 1 Schematic figure comparing E-Ig and anti-sLeX/A staining technique. E-selectin ligands are recognized by using a three-step staining procedure,
where the first staining uses a chimera of mouse E-selectin, i.e. CD62E, with the human IgG Fc (E-Ig). This step is followed by anti-CD62E staining and
HRP polymer detection system. The sLeX/A glycan structure is recognized by using anti-sLeX/A antibody followed by HRP polymer detection system
Fig. 2 Immunohistochemistry staining of colon adenocarcinoma tissue with E-Ig chimera. Brown color indicates positive reactivity and shows
expression of E-selectin ligands in a serial section of the same tissue with 40× magnification (a); 400× magnification (b), 100× magnification (c)
and 600× magnification (d). b is an increased magnification of the boxed area shown in a, demonstrating the high reactivity with goblet cells
(indicated by black arrows) of the crypts and in particular in their apical pole. In d it is highlighted the positive reactivity within the lumens of the
crypts and in the cellular cytoplasm (indicated by black arrow). In a and c the asterisks show the lamina propria with no staining, except for nests of
neoplastic cells indicated by the blue arrows
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Fig. 3 Specificity of the immunohistochemistry staining of colon adenocarcinoma tissue with E-Ig chimera. Images were taken with a 10× magnification,
in sequences from the same tissue section of the same paraffin block of tumor tissue. Brown colour indicates positive reactivity and shows expression of
E-selectin ligands (a). For control staining was performed in the absence of E-Ig (b), absence of anti-CD62E monoclonal antibody (c) and in presence of a
calcium chelant - EDTA (d)
Fig. 4 Immunohistochemistry staining of colon adenocarcinoma and normal colon tissue with E-Ig chimera and HECA-452 antibody. The E-Ig
chimera that recognizes selectin ligands was used to stain colon adenocarcinoma (a) or normal colon (c) tissues, with 40× magnification. The
HECA-452 antibody, that recognizes sLeX and sLeA glycans, was used to stain colon adenocarcinoma (b) or normal colon (d) tissues. In case of
tumor tissue, images were also taken in sequences from the same tissue section of the same paraffin block of tumor tissue. Brown color indicates
E-Ig or HECA-452 reactivity. In adenocarcinoma, the lamina propria showed E-Ig staining exclusively on nests of neoplastic cells, while HECA-452
staining showed positive scattered staining. In normal tissue, both E-Ig chimera and HECA-452 stains the lumens of the crypts and, in particular,
the goblet cells
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the aberrant expression of sLeX/A epitopes by cancer cells
is usually associated with higher propensity for cancer
progression and metastization. For instance, in gastric
cancer, sLeX expression is an independent risk factor for
liver metastasis [9]. In mammary carcinoma, sLeX
expression is associated with a higher risk of metastasis
[10], and in prostatic carcinoma, sLeX is also associated
with poor prognosis [18]. However, despite the fact that
expression of sLeX/A is closely associated with selectin
ligand binding, it is not in itself predictive of E-selectin lig-
and activity [19].
Here, we have provided evidence of successful staining
of paraffin-embedded tissue with a three-step procedure
using an E-selectin chimera (E-Ig). The three-step pro-
cedure staining using E-Ig is able to amplify the signal
intensity to levels comparable to those obtained using
antibodies for immunohistochemistry. Moreover, the use
of this E-Ig staining strategy E-Ig staining was more
specific for cancer cells, compared with anti-sLeX/A
antibody staining that presented a more diffuse pattern
especially with non-specific staining in the lamina pro-
pria. These relative differences may be due to the fact
that while sLeX/A serves as a binding determinant, only
the clustered display of these tetrasaccharides on specific
protein and/or lipid scaffolds determines E-selectin lig-
and activity [25]. The scaffold is necessary to create suf-
ficient sLeX and/or sLeA density to engender E-selectin
binding [5, 20, 26]. Notably all available anti-sLeX/A
antibodies, such as HECA-452, cannot block E-selectin
binding [27] and blockade of E-selectin, with anti-E-
selectin antibodies, is much more effective in blocking
cell adhesion to endothelium [28, 29].
The E-Ig staining recated to goblet cells, in both normal
and tumor tissue, and in particular to their apical mem-
brane. This is consistent with the fact that goblet cells are
the main producers of mucus in colon, consisting essentially
Fig. 5 Immunohistochemistry staining of triple negative breast cancer and lung adenocarcinoma tissues with E-Ig chimera and HECA-452 monoclonal
antibody. E-Ig was used for staining the E-selectin ligands in triple negative breast cancer (a and c) and in lung adenocarcinoma (e and g) tissues. sLeX
and sLeA were stained with HECA-452 antibody in triple negative breast cancer (b and d) and in lung adenocarcinoma (f and h) tissues. Brown color
indicates E-Ig or HECA-452 positive reactivity. Images were taken in sequences from the same tissue section of the same paraffin block of tumor tissue,
with a 10× magnification
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of mucins, which are glycosylated and are well known
E-selectin ligands in colon cancer [30, 31]. Neverthe-
less, the E-selectin staining method here described re-
trieves a more specific staining with less background
signal around the goblet cells. This improvement al-
lows better evaluation of the tissue structure, as well
as the relative analysis of the quantity of granules that
are inside it, which may have clinical and diagnostic
significance.
The detection of neoplastic cells based on E-Ig chimera
staining was also effective in other types of cancer, besides
colon adenocarcinoma, namely in triple negative breast
cancer and in lung adenocarcinoma, which allows us to
conclude that it is a universal technique. Interestingly, the
staining levels of E-selectin ligands are consistent with the
degree of mucus production of these tissues. In fact, as in
the gastrointestinal epithelium, the respiratory epithelium
also has a significant number of goblet cells that are re-
lated to mucins production.
The immunohistochemical staining with E-Ig here de-
scribed was performed using the Lab Vision PTM, which
combines deparaffinization, rehydration, and unmasking
in one step. As an alternative, classic methods of de-
paraffinization can be used, and citrate buffer can also
be utilized during 30 min at 98 °C to perform antigen re-
trieval. Blockade of non-specific binding is critical to ob-
tain specific results. In this protocol, Tween 20
containing buffers, such as TBST has been used and all
antibodies/chimera dilutions were performed using Dia-
mond antibody diluent, which contains bovine serum al-
bumin, as blocking agent. As an alternative, antibody
and E-Ig dilution can be performed in TBST following a
pre-blocking step with 5% BSA in TBST for 10 min, thus
being necessary to adjust the dilution of E-Ig and rat
anti-mouse CD62E antibody as appropriate. One of the
critical aspects of the E-Ig staining protocol described
here is incubation in the presence of calcium, since the
binding of E-selectin receptor to E-selectin ligands is
calcium-dependent. Therefore, it’s necessary to add up
to 2 mM of CaCl2 to both staining and washing buffer
solutions. Binding specificity must be always confirmed
using EDTA chelation, which has the ability to “seques-
ter” calcium, diminishing its reactivity and inhibiting the
binding of E-Ig to E-selectin ligands. In this protocol, we
verified that adding 10 mM EDTA to both staining and
washing buffer solutions, there was an efficient inhib-
ition of the E-Ig staining to colon tissues. During E-Ig
staining, the use of a secondary antibody, rat anti-mouse
CD62E, is critical since the HiDef amplification and
HRP polymer solutions bind to rat Ig Fc regions and do
not recognize the human Ig Fc region contained in E-Ig
chimera molecules. Importantly, non-specific binding of
the secondary antibody must always be excluded. As an
alternative to HiDef amplification and HRP polymer
solutions, one can use an anti-rat IgG antibody conju-
gated with HRP.
In addition, the protocol can be further adapted to
other techniques such as immunofluorescence. This
would depend on the reporter system used, i.e., the re-
porter conjugated into the final step. In Additional file 1:
Figure S1, it is possible to observe the identification of
E-selectin ligands in tumor CF1T_cells [23], by adapting
the present protocol to include a secondary antibody
conjugated to a fluorescent reporter.
In our view, the use of E-Ig chimera staining is more ef-
fective than sLeX/A antibodies since the staining is done
directly on the ligands which effectively have the potential
to bind to E-selectin, including sialofucosylated ligands
which are not detected by the generally used antibodies,
like HECA-452. Although the assays conducted by immu-
nohistochemistry are limited as they do not directly ad-
dress the capacity of cells to bind to endothelium, when
they are circulating in the vascular flow, the correct identi-
fication of E-selectin ligands with E-Ig chimera in the tis-
sue, can simulate the potential of these cells to metastazise.
In this way, the analysis of the metastization potential of
the tissue is done in a more integrated way and considering
the physiological aspects of ligand binding to E-selectin.
Conclusions
The E-Ig staining technique here described allowed for
qualitative and semi-quantitative analysis of E-selectin li-
gands expression and location on colon adenocarcinoma
cells and it may be applied to stain other tissues. The devel-
opment of cancer-specific immunohistochemical staining
methods is of paramount relevance, since the tumor tissue
samples are often obligatory stored and used in the form of
paraffin-embedded blocks, for diagnosis and for patient
stratification. As E-selectin ligands play a fundamental role
in the metastatic processes of cancer cells of several cancer
types, including various adenocarcinomas, this staining
technique will also facilitate our understanding of the mo-
lecular basis of tumor progression and metastasis.
Additional file
Additional file 1: Figure S1. Example of application of staining of
E-selectin ligands by Immunofluorescence. Staining of E-selectin ligands in
CF1_T cells. The breast cancer cell line CF1_T has a high content of E-selectin
ligands and it was obtained and cultured as described by Carrascal et al.
(2017). Cells were cultured on glass coverslips overnight and then fixed with
3.7% paraformaldehyde. After blocking with 1% bovine serum albumin, cells
were stained with E-Ig chimera in the presence of 2 mM CaCl2. The final step
included anti-human Ig antibody conjugated with fluorescein (FITC, green), in
the presence of PBS containing 2 mM CaCl2 (A). Control experiments were
processed in the absence of CaCl2 (B). After permeabilization with 0.1%
TritonX-100, F-actin was stained with Alexa Fluor 568 phalloidin (Molecular
Probes, Leiden, Netherlands). Images were acquired with a Leica TCS SP2
AOBS confocal microscope. A representative cross-section confocal images
were selected after Z-stacking. (PPTX 230 kb)
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